Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will hold its 2024 Investor Day on Thursday, September 19, starting at 9:00 a.m. (ET) in New York City. The format will feature presentations by members of Thermo Fisher Scientific's senior management team and conclude with a Q&A session. The live webcast of the presentation can be accessed via the Investors section of our website, www.thermofisher.com. A replay of the webcast wi.

Thermo Fisher Scientific to Host Investor Day

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2024. First Quarter 2024 Highlights First quarter revenue was $10.34 billion. First quarter GAAP diluted earnings per share (EPS) increased 4% to $3.46. First quarter adjusted EPS increased 2% to $5.11. Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the qu.

Thermo Fisher Scientific Reports First Quarter 2024 Results

Align Technology

Boston Scientific

ICON

Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how BSX, TMO, ALGN and ICLR fare this time.

What's in Store for These 4 Medical Products Stocks in Q1 Earnings?

Evaluate the expected performance of Thermo Fisher (TMO) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Seeking Clues to Thermo Fisher (TMO) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

IDEXX Laboratories

Investors looking for stocks in the Medical - Instruments sector might want to consider either Thermo Fisher Scientific (TMO) or Idexx Laboratories (IDXX). But which of these two stocks offers value investors a better bang for their buck right now?

TMO vs. IDXX: Which Stock Is the Better Value Option?

Strength in Analytical Instrument and Laboratory Products and Services segments are likely to have driven Thermo Fisher's (TMO) first-quarter 2024 performance.

What's in Store for Thermo Fisher (TMO) in Q1 Earnings?

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, has introduced the Gibco™ CTS™ OpTmizer™ One Serum-Free Medium (CTS OpTmizer One SFM)*, a novel animal origin-free (AOF) formulation designed specifically for clinical and commercial cell therapy manufacturing to deliver increased scalability and performance of T cell expansion. As a result, cell therapy manufacturers can use CTS OpTmizer One SFM to help optimize their workflows and get T cell t.

Thermo Fisher Scientific Introduces Animal Origin-Free Formulation to Support Scaling of Cell Therapy Manufacturing

Abbott Labs

CVS Health

Johnson & Johnson

Patterson Companies

Pfizer

UnitedHealth Group

With rising concerns in the market potentially forcing a strategic shift, investors may want to consider healthcare stocks. No matter what happens, people need access to health-related products and services.

7 Healthcare Stocks to Keep Your Portfolio in Tip-Top Shape

Thermo Fisher (NYSE: TMO ) layoffs are in the news Tuesday after the biopharma services company announced job cuts at its California plasmid manufacturing location. According to these latest reports, Thermo Fisher is going to cut 74 jobs from the facility starting May 31, 2024.

Thermo Fisher Layoffs 2024: What to Know About the Latest TMO Job Cuts

Thermo Fisher's (TMO) new ENERGY STAR-certified TSX Universal Series ULT Freezers deliver tighter temperature control and faster recovery times.

Thermo Fisher (TMO) Launches TSX Universal Series ULT Freezers

MUNICH--(BUSINESS WIRE)--Analytica 2024 - Thermo Fisher Scientific, Inc. is debuting its recently launched innovative products, hosting educational presentations and showcasing live lab demos for customers working in laboratory technology, analysis, biotechnology, and environmental quality during the 2024 Analytica Conference. “Advancements in data analytics and optimized laboratory workflows that enable fast, precise analysis are key to propelling the field of analytical science forward,” said.

Thermo Fisher Scientific Innovations at Analytica 2024 Optimize Workflows and Enable Precise Analysis Across Life Sciences, Applied and Industrial Markets

CARLSBAD, Calif.--(BUSINESS WIRE)--Building on 80 years of expertise engineering cold storage lab equipment, Thermo Fisher Scientific today introduces its newest line of high performance, ultra-low temperature (ULT) freezers. With enhancements to performance, user experience and energy efficiency, the Thermo Scientific™ TSX™ Universal Series ULT Freezers seamlessly adapt to scientists' workflows across a variety of lab settings, marking a new era in performance, reliability, and sustainability.

Thermo Fisher Scientific Launches New ENERGY STAR certified TSX Universal Series ULT Freezers to Deliver Tighter Temperature Control and Faster Recovery Times

Thermo Fisher (TMO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Thermo Fisher Scientific Inc. (TMO) is Attracting Investor Attention: Here is What You Should Know

Thermo Fisher's (TMO) new LInspector Edge In-line Mass Profilometer delivers real-time, full-coverage mass loading analysis for battery electrode coating.

Thermo Fisher (TMO) Debuts a New In-Line Metrology Solution

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2024 before the market opens on Wednesday, April 24, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The.

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 24, 2024

Taiwan Semiconductor Manufacturing

Visa

Let's take a look at three mega-cap stocks to own. A mega-cap company is traditionally thought of as a firm with a market capitalization of at least $200 billion.

Megatrends, Mega Profits: 3 Mega-Cap Stocks to Own

Strength in end markets and strategic collaborations bode well for Thermo Fisher (TMO).

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

In the closing of the recent trading day, Thermo Fisher Scientific (TMO) stood at $579.37, denoting a +1.85% change from the preceding trading day.

Thermo Fisher Scientific (TMO) Exceeds Market Returns: Some Facts to Consider

WALTHAM, Mass.--(BUSINESS WIRE)--To address the needs of the rapidly growing battery market, Thermo Fisher Scientific today introduced the Thermo Scientific™ LInspector™ Edge In-line Mass Profilometer, which delivers full-width electrode mass loading measurement and provides battery manufacturers with the data needed to make better, safer batteries, more efficiently. The LInspector Edge analyzer introduces the next generation of metrology capabilities through a new analytical technique, in-line.

Thermo Fisher Scientific Announces a New In-line Metrology Solution to Improve Battery Safety and Performance

Thermo Fisher Scientific (TMO) concluded the recent trading session at $568.82, signifying a -0.83% move from its prior day's close.

Thermo Fisher Scientific (TMO) Falls More Steeply Than Broader Market: What Investors Need to Know

Thermo Fisher's (TMO) new partnership with Bayer AG is likely to help increase the latter's precision cancer therapies.

Thermo Fisher (TMO) Inks Deal to Develop Companion Diagnostics

In the closing of the recent trading day, Thermo Fisher Scientific (TMO) stood at $580.05, denoting a -0.46% change from the preceding trading day.

Thermo Fisher Scientific (TMO) Stock Declines While Market Improves: Some Information for Investors

Bayer AG

BERLIN & CARLSBAD, Calif.--(BUSINESS WIRE)--Bayer AG and Thermo Fisher Scientific Inc. today announced a collaboration to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients who may benefit from Bayer's growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time. The CDx will be developed using Thermo Fisher's Oncomine Dx Express Test* on the Ion Torrent Genexus Dx Sy.

Bayer and Thermo Fisher Scientific Collaborate to Increase Patient Access to Precision Cancer Medicines

BERLIN & CARLSBAD, Calif.--(BUSINESS WIRE)--Bayer AG and Thermo Fisher Scientific Inc. today announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients who may benefit from Bayer's growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time. The CDx will be developed using Thermo Fisher's Oncomine Dx Express Test* on the Ion Torrent Genexus Dx System*, a fully i.

Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines

Thermo Fisher Scientific (TMO) reachead $580.05 at the closing of the latest trading day, reflecting a -0.7% change compared to its last close.

News for Thermo Fisher Scientific Stock (TMO)